Lupin Limited (commonly "Lupin"; NSE/BSE: LUPIN) is an Indian multinational pharmaceutical company headquartered in Mumbai (Kalpataru Inspire, Santa Cruz East). It was founded in 1968 by Dr. Desh Bandhu Gupta, with the listed entity incorporated in 1983; the company remains publicly traded with the founder's family holding a controlling interest. FY2025 disclosures report gross sales of roughly ₹22,192 crore (about US$2.3 billion) and a workforce of more than 24,000 employees; market capitalization has been reported around ₹1.1 trillion. Its U.S. subsidiary, Lupin Pharmaceuticals, Inc., is based in Baltimore, Maryland.
Lupin is an operating pharmaceutical manufacturer, not a patent-assertion entity. Its business spans branded and generic formulations, active pharmaceutical ingredients (APIs), complex generics, biosimilars and biotechnology products, and drug-delivery systems. Major therapeutic areas include cardiology, anti-diabetes, respiratory, central nervous system, gastrointestinal, anti-infectives, oncology and anti-tuberculosis, with market leadership reported in the Indian anti-TB segment. It sells across more than 100 markets, with the U.S., India, Japan and other emerging markets as key regions, and also operates a consumer-health arm (LupinLife).
Patent-litigation posture: Lupin appears in the tracked data solely as a defendant (0 plaintiff cases, 1 defendant case), consistent with a large generic manufacturer that is frequently named in Hatch-Waxman and related antitrust disputes rather than itself asserting patents. Its single tracked matter sits in the U.S. District Court for the Northern District of California, not a plaintiff-friendly venue like the Eastern District of Texas.
Notable case: In re Xyrem (Sodium Oxybate) Antitrust Litigation (N.D. Cal., MDL No. 3:20-md-02966), concerning allegations that brand-maker Jazz Pharmaceuticals and several generic defendants (including Hikma, Amneal, Par and Lupin) entered settlements delaying generic sodium oxybate competition. Lupin and Amneal settled with the class for a combined $3.4 million, with Lupin contributing about $1.5 million; the court granted final approval in April 2024. Claims against remaining defendants continued.